The Lancet Infectious Diseases: Chinese vaccine candidate ba

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published today in The Lancet Infectious Diseases journal, finding the formulation appears safe and induces an antibody response in healthy volunteers aged 18 to 59 years

Related Keywords

Suining , Sichuan , China , Turkey , Brazil , Zhejiang , Indonesia , Nanjing , Jiangsu , Beijing , Chinese , Fengcai Zhu , Sinovac Life Sciences , Development Program , Chinese Academy Of Sciences , Jiangsu Provincial Center , Technology Program , Zhejiang Provincial Center , Chinese National Key Research , National Institute For Food , Sinovac Biotech , Suining County Center , Johns Hopkins University , Lancet Infectious Diseases , Disease Control , Suining County , Gang Zeng , National Institute , Drug Control , Chinese Academy , Sinovac Life , Beijing Science ,